Topical nasal steroids for intermittent and persistent allergic rhinitis in children

Sayyad, Jamal J Al; Fedorowicz, Zbys; Alhashimi, Dunia; Jamal, Ahmed

doi:10.1002/14651858.cd003163.pub4

Cited by 37 publications

(13 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The articles included epidemiologic studies in the general population (cross-sectional [16][17][18][19][20][21][22][23] and cohort 24 ), observational studies among primary care physicians and specialists, and interventional studies, including 5 large-scale, double-blind, placebocontrolled trials. [25][26][27][28][29] Three Cochrane Collaboration reviews using the ARIA classification have been finalized, [30][31][32] and others are pending.…”

Section: Scientific Publications Using the Aria Classificationmentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs

Bousquet¹,

Schünemann²,

Samoliński³

et al. 2012

Journal of Allergy and Clinical Immunology

519

377

View full text Add to dashboard Cite

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.

show abstract

Section: Scientific Publications Using the Aria Classificationmentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs

Bousquet¹,

Schünemann²,

Samoliński³

et al. 2012

Journal of Allergy and Clinical Immunology

519

377

View full text Add to dashboard Cite

show abstract

“…15 A systematic review of nasal corticosteroids in children with allergic rhinoconjunctivitis applied such strict selection criteria that only three small old studies with methodological flaws were included. 16 The most common local side effect is epistaxis (nose bleeds), which occurs in 17-23% of patients, although it is also common (10-15%) in patients treated with placebo in clinical trials. 17 Therefore, local trauma caused by the nozzle of the nose spray probably causes epistaxis in many cases, rather than the drug itself.…”

Section: Intranasal Glucocorticosteroidsmentioning

confidence: 99%

Allergic rhinoconjunctivitis in children

Groot

Brand²,

Fokkens³

et al. 2007

BMJ

View full text Add to dashboard Cite

“…In children, they should be used at the lowest dose that controls symptoms, particularly when used concurrently with other inhaled or intranasal steroids. 17 Occasionally, intranasal steroids may be associated with dryness, crusting, or slight bleeding, which if recurrent may necessitate withdrawal of treatment.…”

Section: Swabs Smears and Biopsiesmentioning

confidence: 99%